The Study of Concurrent Chemoradiation with EP Regimen in Limited Stage Small Cell Lung Cancer

Objective 　To investigate the outcomes and toxicities in 42 patients with limited stage small cell lung cancer (SCLC) treated with concurrent chemoradiothery. Methods 　The patients received EP regimen. Cisplatin (DDP) was administ rated with 25mg. m^{- 2}, d1 - 3 ; Etop side (VP - 16) 100mg. m^{- 2}, d1- 3, repeated every 21 days for 4 - 6 cycles. Irradiation was performed in conventional f raction (2 Gy per fraction per day, 5 days in a week) with total dose (DT) 54～60 Gy. Results 　The acute toxicities included the incidence of radiation pneumotitis was 62 %, Total and grade 3 or 4 radiation esophagititis rates were 79 % and 12 % respectively. And grade 3 or 4 neut ropenia was 21 %. The 1 - year, 2 - year, 3 - year local cont rol rate and overall survival rate were 88 %, 79 %, 71 % and 86 %, 55 %, 24 % respectively. Conclusion 　Concurrent chemoradiation with EP regimen in limited stage SCLC patient s is acceptable. Both local cont rol rate and overall survival rate are improved. The late toxicities and longer overall survival need further follow - up.